Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin‐induced apoptosis

BACKGROUND: Delanzomib, a novel proteasome inhibitor, has demonstrated promising efficacy and antitumor ability in human multiple myeloma cell lines and patient‐derived cells. However, the potential therapeutic effects of delanzomib on breast cancer remain unknown. In this study, we show that delanz...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Thorac Cancer
Main Authors: Wang, Mopei, Liang, Li, Lu, Jiaxiong, Yu, Yang, Zhao, Yanling, Shi, Zhenfeng, Li, Hui, Xu, Xin, Yan, Yuxian, Niu, Yan, Liu, Zhentao, Shen, Lin, Zhang, Hong
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons Australia, Ltd 2019
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6449274/
https://ncbi.nlm.nih.gov/pubmed/30883017
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13030
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados